RNXT

BEARISH

$1.0 Live

RenovoRx, Inc. · NASDAQ

Target $6.88 (+587.5%)

$0.7 52W Range $1.45

RNXT RenovoRx, Inc. - Fundamental Analysis

BEARISH

Console Chart News

RNXT Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Biotechnology

Current Price Live

$1.0

Analyst Target

$6.88

+587.5% Upside

52W High

$1.45

52W Low

$0.7

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 19, 2026

Market cap

$45.05M

P/E

N/A

ROE

-225.6%

Profit margin

N/A

Debt/Equity

0.04

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

85%

RNXT exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 1/9, indicating severe financial distress and poor operational efficiency. While the company maintains a strong liquidity position with a current ratio of 4.02 and very low debt, it is burning cash at an unsustainable rate with an operating margin of -1269.75%. The valuation is disconnected from fundamentals, trading at a Price/Sales ratio of 40.12. Despite aggressive 'strong buy' analyst targets of $6.88, the deterministic data suggests a high-risk speculative profile with a long-term bearish price trend.

Key Strengths

Strong short-term liquidity (Current Ratio: 4.02)

Very low leverage (Debt/Equity: 0.04)

Explosive year-over-year revenue growth (453.50%)

Improving EPS trajectory (YoY growth +33.3%)

Strong analyst conviction with a high target price ($6.88)

Key Risks

Extreme operational inefficiency (Operating Margin: -1269.75%)

Severe fundamental health failure (Piotroski F-Score: 1/9)

Extreme valuation premium (Price/Sales: 40.12)

Significant long-term capital erosion (5Y Change: -86.2%)

Negative return on equity (-225.62%) indicating value destruction

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

Speculative/High Risk

Key drivers: Piotroski F-Score 1/9, Operating Margin -1269%, P/S Ratio 40.12, Strong Current Ratio

Confidence

90%

Value

10/100

Ref P/E, PEG, Graham Number

Positives

No standout positives identified.

Watchpoints

P/S ratio of 40.12 is extremely high
P/B ratio of 6.76 is elevated for a non-profitable entity
No Graham Number available due to lack of earnings

Future

50/100

Ref Growth rates

Positives

High YoY revenue growth
Strong analyst price targets

Watchpoints

Lack of path to profitability
High cash burn rate

Past

15/100

Ref Historical trends

Positives

Recent EPS surprises have been mostly positive

Watchpoints

5-year price decline of 86.2%
Consistent quarterly losses

Health

20/100

Ref Altman Z-Score, Piotroski F-Score

Positives

Low Debt/Equity
High Current Ratio

Watchpoints

Piotroski F-Score of 1/9 is a critical warning sign
Negative ROE and ROA

Dividend

0/100

Ref Yield, Payout

Positives

No standout positives identified.

Watchpoints

No dividend paid
No capacity for dividends

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$1.0

Analyst Target

$6.88

Upside/Downside

+587.5%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for RNXT and closest competitors.

Updated 2026-04-17

Company	5Y	3Y	1Y	6M	1M	1W
RNXT RenovoRx, Inc. Primary	-86.2%	-68.2%	-2.0%	-10.7%	-2.9%	+1.5%
POM Pomdoctor Limited Peer	-90.5%	-90.5%	-90.5%	-91.4%	-7.3%	+17.2%
ONMD OneMedNet Corporation Peer	-91.1%	-91.8%	+65.5%	-68.2%	+9.7%	+2.6%
ARAY Accuray Incorporated Peer	-93.2%	-87.0%	-78.7%	-76.4%	-27.4%	-24.4%
IMMP Immutep Limited Peer	-91.1%	-80.6%	-78.0%	-84.6%	-88.8%	-13.9%

RNX

RenovoRx, Inc.

Primary

-86.2%

-68.2%

-2.0%

-10.7%

-2.9%

+1.5%

POM

Pomdoctor Limited

Peer

-90.5%

-91.4%

-7.3%

+17.2%

ONM

OneMedNet Corporation

Peer

-91.1%

-91.8%

+65.5%

-68.2%

+9.7%

+2.6%

ARA

Accuray Incorporated

Peer

-93.2%

-87.0%

-78.7%

-76.4%

-27.4%

-24.4%

IMM

Immutep Limited

Peer

-91.1%

-80.6%

-78.0%

-84.6%

-88.8%

-13.9%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

-8.33

N/A

6.76

40.12

34.05

-3.19

$45.05M

Profitability

Profit margins and return metrics

Profit Margin N/A

Operating Margin -1269.75%

Gross Margin 70.88%

ROE -225.62%

ROA -92.59%

Growth

Revenue and earnings growth rates

Revenue Growth +453.5%

Earnings Growth N/A

Q/Q Revenue Growth +453.49%

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.04

Low debt

Current Ratio

4.02

Strong

Quick Ratio

3.65

Excellent

Cash/Share

$0.16

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue

$0.0B

Gross Margin

88.2%

Op. Margin

-1480.3%

Net Margin

-1235.7%

Total Assets

$0.0B

Liabilities

$0.0B

Equity

$0.0B

Debt/Equity

0.49x

Operating CF

$-0.0B

Free Cash Flow

$-0.0B

FCF Yield

100%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-03-30

$-0.08

2025-11-13

$-0.08

2025-08-14

$-0.08

+5.9% surprise

2025-08-14

$N/A

Healthcare Sector Comparison

Comparing RNXT against 447 companies in the Healthcare sector (26 bullish, 140 neutral, 281 bearish)

Return on Equity (ROE)

-225.62%

This Stock

-97.42%

Sector Avg

+131.6% (Excellent)

Debt to Equity

0.04

This Stock

3.06

Sector Avg

-98.7% (Less Debt)

Revenue Growth

453.5%

This Stock

147.85%

Sector Avg

+206.7% (Fast Growth)

Current Ratio

4.02

This Stock

4.68

Sector Avg

-14.0% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
RNXT RenovoRx, Inc.	BEARISH	$45.05M	-	-225.6%	-%	$1.0
POM Pomdoctor Limited	BEARISH	$45.43M	-	-%	-40.6%	$0.38	Compare
ONMD OneMedNet Corporation	BEARISH	$46.04M	-	-%	-206.1%	$0.88	Compare
ARAY Accuray Incorporated	BEARISH	$44.0M	-	-70.3%	-8.2%	$0.37	Compare
IMMP Immutep Limited	BEARISH	$46.14M	-	-61.8%	-%	$0.31	Compare

RNXT RenovoRx, Inc.

BEARISH

Mkt Cap

$45M

P/E

ROE

-225.6%

Price

$1.0

POM Pomdoctor Limited

Compare with RNXT

ONMD OneMedNet Corporation

Compare with RNXT

ARAY Accuray Incorporated

Compare with RNXT

Compare with RNXT

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

Date	Insider	Position	Transaction	Shares	Value
2026-04-02	VOLL MARK	Chief Financial Officer	Stock Award	80,000	-
2026-03-25	VOLL MARK	Chief Financial Officer	Stock Award	12,380	-
2026-03-20	VOLL MARK	Chief Financial Officer	Purchase	97,200	$97,200
2026-03-20	MARTON LAURENCE	Director	Purchase	9,720	$9,720
2026-03-20	BAGAI SHAUN R.	Chief Executive Officer	Purchase	24,300	$24,300
2026-01-21	AGAH RAMTIN M.D.	Officer and Director	Purchase	10,000	$9,975
2025-12-31	AGAH RAMTIN M.D.	Officer and Director	Purchase	9,795	$8,424
2025-12-30	AGAH RAMTIN M.D.	Officer and Director	Purchase	205	$169
2025-12-18	BAGAI SHAUN R.	Chief Executive Officer	Purchase	5,000	$4,506
2025-12-17	BAGAI SHAUN R.	Chief Executive Officer	Purchase	5,000	$4,262
2025-12-16	AGAH RAMTIN M.D.	Officer and Director	Purchase	12,000	$10,200
2025-12-05	AGAH RAMTIN M.D.	Officer and Director	Purchase	10,000	$9,600
2025-11-24	AGAH RAMTIN M.D.	Officer and Director	Purchase	22,000	$17,600

VOLL MARK

Chief Financial Officer

Stock Award

2026-04-02

80,000 shares

VOLL MARK

Chief Financial Officer

Stock Award

2026-03-25

12,380 shares

VOLL MARK

Chief Financial Officer

Buy

2026-03-20

97,200 shares · $97,200

MARTON LAURENCE

Director

Buy

2026-03-20

9,720 shares · $9,720

BAGAI SHAUN R.

Chief Executive Officer

Buy

2026-03-20

24,300 shares · $24,300

AGAH RAMTIN M.D.

Officer and Director

Buy

2026-01-21

10,000 shares · $9,975

AGAH RAMTIN M.D.

Officer and Director

Buy

2025-12-31

9,795 shares · $8,424

AGAH RAMTIN M.D.

Officer and Director

Buy

2025-12-30

205 shares · $169

BAGAI SHAUN R.

Chief Executive Officer

Buy

2025-12-18

5,000 shares · $4,506

BAGAI SHAUN R.

Chief Executive Officer

Buy

2025-12-17

5,000 shares · $4,262

AGAH RAMTIN M.D.

Officer and Director

Buy

2025-12-16

12,000 shares · $10,200

AGAH RAMTIN M.D.

Officer and Director

Buy

2025-12-05

10,000 shares · $9,600

AGAH RAMTIN M.D.

Officer and Director

Buy

2025-11-24

22,000 shares · $17,600

Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

10-K

2026-03-30

RNXT filed its annual 10-K report on March 30, 2026. The provided excerpts do not contain specific financial metrics or detailed risk disclosures to evaluate the company's current performance or risk profile.

8-K

2026-03-30

Renext (RNXT) filed an 8-K on March 30, 2026, likely to announce its financial results for the preceding period.

8-K

2026-03-27

8-K

2026-03-23

8-K

2026-02-06

Renext (RNXT) filed an 8-K on February 6, 2026, likely to report its fourth-quarter and full-year financial results.

8-K

2026-01-02

RNXT filed an 8-K on January 2, 2026, likely to report year-end financial results or a material corporate update.

8-K

2025-11-14

8-K

2025-11-13

10-Q

2025-11-13

RNXT filed its 10-Q on November 13, 2025. While specific financial highlights were not provided in the excerpt, the filing includes a section detailing risk factors under Item 1A.

8-K

2025-08-14

Renext (RNXT) filed an 8-K on August 14, 2025, likely to announce its second-quarter financial results.

10-Q

2025-08-14

8-K

2025-06-25

8-K

2025-05-15

10-Q

2025-05-15

DEF 14A

2025-04-30

Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

STRONG_BUY

4 analysts

Ascendiant Capital

2026-04-09

Maintains

Buy Buy

HC Wainwright & Co.

2026-04-08

reit

Buy Buy

Ascendiant Capital

2026-02-17

Maintains

Buy Buy

Ascendiant Capital

2025-11-21

Maintains

Buy Buy

Past News Coverage

Recent headlines mentioning RNXT from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

RNXT

RNXT RenovoRx, Inc. - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Recent Insider Trading

SEC Filings

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!